NCT07632742 Moses 2.0 vs Magneto for HoLEP - a Randomized Controlled Trial
| NCT ID | NCT07632742 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Northwestern University |
| Condition | Enlarged Prostate (BPH) |
| Study Type | INTERVENTIONAL |
| Enrollment | 180 participants |
| Start Date | 2026-05-29 |
| Primary Completion | 2027-06 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 180 participants in total. It began in 2026-05-29 with a primary completion date of 2027-06.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The objective of this study is to compare the Magneto 150 holmium laser to the current MOSES 2.0 technology to see if there is a benefit in decreased hemostasis time intraoperatively.
Eligibility Criteria
Inclusion Criteria: * Undergoing HoLEP for the treatment of bothersome lower urinary tract symptoms * Internet access and a device to complete postoperative questionnaires (smartphone, tablet, laptop or desktop computer) Exclusion Criteria: * Patients who lack decisional capacity * Patients unable to read/speak English * Patients who are on a blood thinner (anticoagulation medication) * Patients who do not have internet access to complete postoperative surveys
Contact & Investigator
Perry Xu, MD
PRINCIPAL INVESTIGATOR
Northwestern University
Frequently Asked Questions
Who can join the NCT07632742 clinical trial?
This trial is open to male participants only, aged 18 Years or older, up to 100 Years, studying Enlarged Prostate (BPH). Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07632742 currently recruiting?
Yes, NCT07632742 is actively recruiting participants. Contact the research team at alyssa.mcdonald@northwestern.edu for enrollment information.
Where is the NCT07632742 trial being conducted?
This trial is being conducted at Chicago, United States.
Who is sponsoring the NCT07632742 clinical trial?
NCT07632742 is sponsored by Northwestern University. The principal investigator is Perry Xu, MD at Northwestern University. The trial plans to enroll 180 participants.